FDA Approved: SIMVASTATIN — Supplemental Application (XLCare Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for simvastatin submitted by XLCare Pharmaceuticals Inc., approving changes under the ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Coronary Artery Disease
• Hyperlipidemia

Drugs mentioned

• SIMVASTATIN (SIMVASTATIN)

Snippet

SUPPL AP for SIMVASTATIN (SIMVASTATIN)